- Home
- ETON vs EYEN Comparison
ETON vs EYEN Comparison
Compare ETON & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- EYEN
- Stock Information
- Founded
- ETON 2017
- EYEN 2014
- Country
- ETON United States
- EYEN United States
- Employees
- ETON N/A
- EYEN N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- EYEN Health Care
- Exchange
- ETON Nasdaq
- EYEN Nasdaq
- Market Cap
- ETON 428.5M
- EYEN 2.9M
- IPO Year
- ETON 2018
- EYEN 2018
- Fundamental
- Price
- ETON $14.07
- EYEN $10.22
- Analyst Decision
- ETON Strong Buy
- EYEN Hold
- Analyst Count
- ETON 3
- EYEN 4
- Target Price
- ETON $29.67
- EYEN $2.00
- AVG Volume (30 Days)
- ETON 635.9K
- EYEN 10.0M
- Earning Date
- ETON 08-07-2025
- EYEN 08-11-2025
- Dividend Yield
- ETON N/A
- EYEN N/A
- EPS Growth
- ETON N/A
- EYEN N/A
- EPS
- ETON N/A
- EYEN N/A
- Revenue
- ETON $48,327,000.00
- EYEN $67,063.00
- Revenue This Year
- ETON $103.21
- EYEN $7,680.45
- Revenue Next Year
- ETON $51.34
- EYEN $315.38
- P/E Ratio
- ETON N/A
- EYEN N/A
- Revenue Growth
- ETON 40.88
- EYEN 663.82
- 52 Week Low
- ETON $3.22
- EYEN $0.85
- 52 Week High
- ETON $21.48
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- ETON 26.60
- EYEN 69.20
- Support Level
- ETON $13.09
- EYEN $3.68
- Resistance Level
- ETON $14.18
- EYEN $11.40
- Average True Range (ATR)
- ETON 0.78
- EYEN 2.03
- MACD
- ETON -0.23
- EYEN 0.58
- Stochastic Oscillator
- ETON 8.78
- EYEN 73.25
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.